Arthrone key facts
as of Oct 2026- Developer and manufacturer of orthopaedic medical devices designed to restore joint function and treat musculoskeletal conditions.
- Arthrone is valued at approximately $111.0M as of Oct 2026 (last reported valuation).
- It has raised $51.1M; the latest was Later Stage VC ($21.8M) in Apr 2026.
- Notable investors include Addor Capital, Cowin Capital, Founder Hesheng Investment, SAIF Partners, CDIB Capital International — 19 tracked in total.
- Status: Privately Held (backing).
Arthrone's last reported valuation, Aug 2023. Nothing priced has surfaced since.
- ·The complete investor list: 19 names
- ·Watch Arthrone: the Monday email on marks, rounds and moves
Arthrone funding rounds
No funding rounds for Arthrone are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Arthrone
19+Arthrone valuation
Arthrone's last reported valuation was $111 million in Aug 2023. No priced round, secondary trade or fund mark has surfaced since.
Arthrone investors
19 investors are on record for Arthrone, including Addor Capital, Cowin Capital, Founder Hesheng Investment and SAIF Partners.
About Arthrone
Developer and manufacturer of orthopaedic medical devices designed to restore joint function and treat musculoskeletal conditions. The company offers ceramic-based joint prostheses, spine and dental implants, and sports medicine devices, enabling healthcare providers to perform precise surgical interventions and improve patient mobility outcomes.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2017
- Employees
- 43
- Website
- arthrone.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.